{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:14:26Z","timestamp":1792599266645,"version":"4.5.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmcd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.numecd.2026.104755","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T09:04:12Z","timestamp":1775898252000},"page":"104755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bempedoic acid and increased serum uric acid levels: a matter of concern?"],"prefix":"10.1016","volume":"36","author":[{"given":"Luca","family":"Bonanni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Biolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Marodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Portinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8898-7441","authenticated-orcid":false,"given":"Nicola","family":"Ferri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.numecd.2026.104755_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13457","article-title":"Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis","volume":"7","author":"Pinkosky","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.numecd.2026.104755_bib2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104755_bib3","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamacardio.2020.2314","article-title":"Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia","volume":"5","author":"Banach","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2026.104755_bib4","first-page":"3167","article-title":"Update on the epidemiology, genetics, and therapeutic options of hyperuricemia","volume":"12","author":"Li","year":"2020","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.numecd.2026.104755_bib5","first-page":"121","volume":"vol. 27","author":"Maloberti","year":"2020"},{"key":"10.1016\/j.numecd.2026.104755_bib6","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.numecd.2026.104755_bib7","doi-asserted-by":"crossref","first-page":"15501","DOI":"10.1073\/pnas.0904411106","article-title":"Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy","volume":"106","author":"Preitner","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.numecd.2026.104755_bib8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1681\/ASN.2006040415","article-title":"Human renal organic anion transporter 4 operates as an asymmetric urate transporter","volume":"18","author":"Hagos","year":"2007","journal-title":"J Am Soc Nephrol : JASN (J Am Soc Nephrol)"},{"key":"10.1016\/j.numecd.2026.104755_bib9","doi-asserted-by":"crossref","first-page":"18526","DOI":"10.1074\/jbc.272.30.18526","article-title":"Expression cloning and characterization of a novel multispecific organic anion transporter","volume":"272","author":"Sekine","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.numecd.2026.104755_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000074539","article-title":"Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux","volume":"13","author":"Bakhiya","year":"2003","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.numecd.2026.104755_bib11","doi-asserted-by":"crossref","first-page":"F327","DOI":"10.1152\/ajprenal.00133.2004","article-title":"Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites","volume":"288","author":"Van Aubel","year":"2005","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.numecd.2026.104755_bib12","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0140-6736(08)61343-4","article-title":"Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study","volume":"372","author":"Dehghan","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104755_bib13","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/ard.2008.106856","article-title":"Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout","volume":"69","author":"Urano","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.numecd.2026.104755_bib14","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jacl.2020.08.009","article-title":"Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials","volume":"14","author":"Bays","year":"2020","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2026.104755_bib15","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1080\/15257770.2011.616564","article-title":"Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule","volume":"30","author":"Jutabha","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.numecd.2026.104755_bib16","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C","article-title":"The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients","volume":"43","author":"Caspi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.numecd.2026.104755_bib17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/clpt.2011.223","article-title":"Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers","volume":"91","author":"Butler","year":"2012","journal-title":"Clin Pharmacol Therapeut"},{"key":"10.1016\/j.numecd.2026.104755_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijcard.2015.05.023","article-title":"Ticagrelor-related gout: an underestimated side effect","volume":"192","author":"Zhang","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.numecd.2026.104755_bib19","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1016\/j.transproceed.2005.08.042","article-title":"Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients","volume":"37","author":"Kanbay","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.numecd.2026.104755_bib20","first-page":"611","article-title":"The coronary profile: 12-year follow-up in the Framingham study","volume":"9","author":"Kannel","year":"1967","journal-title":"J Occup Med"},{"key":"10.1016\/j.numecd.2026.104755_bib21","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1001\/jama.283.18.2404","article-title":"Sevum uric acid and cardiovascular mortality - the NHANES I epidemiologic follow-up study, 1971-1992","volume":"283","author":"Fang","year":"2000","journal-title":"JAMA, J Am Med Assoc"},{"key":"10.1016\/j.numecd.2026.104755_bib22","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2796.2009.02133.x","article-title":"Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417 734 men and women in the apolipoprotein MOrtality RISk study (AMORIS)","volume":"266","author":"Holme","year":"2009","journal-title":"J Intern Med"},{"key":"10.1016\/j.numecd.2026.104755_bib23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1161\/ATVBAHA.107.160184","article-title":"Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population -: the MONICA\/KORA cohort study","volume":"28","author":"Meisinger","year":"2008","journal-title":"Arterioscl Throm Vas"},{"key":"10.1016\/j.numecd.2026.104755_bib24","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/archinte.164.14.1546","article-title":"Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men -: a prospective cohort study","volume":"164","author":"Niskanen","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.numecd.2026.104755_bib25","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1161\/01.STR.0000221716.55088.d4","article-title":"Uric acid is a risk factor for myocardial infarction and stroke - the Rotterdam study","volume":"37","author":"Bos","year":"2006","journal-title":"Stroke"},{"key":"10.1016\/j.numecd.2026.104755_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020180","article-title":"Cumulative serum uric acid and its time course are associated with risk of myocardial infarction and all-cause mortality","volume":"10","author":"Tian","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.numecd.2026.104755_bib27","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1161\/STROKEAHA.123.042708","article-title":"Cumulative serum uric acid exposure and its time course with the risk of incident stroke","volume":"54","author":"Tian","year":"2023","journal-title":"Stroke"},{"key":"10.1016\/j.numecd.2026.104755_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/ehjqcco\/qcae054","article-title":"An early accumulation of serum uric acid confers more risk of heart failure: a 10-year prospective cohort study","volume":"11","author":"Tian","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.numecd.2026.104755_bib29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.atherosclerosis.2016.10.006","article-title":"Elevated serum uric acid and risk of cardiovascular or all-cause mortality in people with suspected or definite coronary artery disease: a meta-analysis","volume":"254","author":"Wang","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.numecd.2026.104755_bib30","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/heartjnl-2012-302535","article-title":"The role of uric acid in the pathogenesis of human cardiovascular disease","volume":"99","author":"Kanbay","year":"2013","journal-title":"Heart"},{"key":"10.1016\/j.numecd.2026.104755_bib31","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/acr.20344","article-title":"Hyperuricemia and incident hypertension: a systematic review and meta-analysis","volume":"63","author":"Grayson","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.numecd.2026.104755_bib32","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/HYPERTENSIONAHA.120.16547","article-title":"Urate, blood pressure, and cardiovascular disease: evidence from mendelian randomization and meta-analysis of clinical trials","volume":"77","author":"Gill","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.numecd.2026.104755_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.numecd.2026.104755_bib34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjms.2019.10.017","article-title":"Uric acid level as a predictor of long-term mortality in advanced age population","volume":"359","author":"Abu","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.numecd.2026.104755_bib35","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejim.2017.07.021","article-title":"Uric acid level as predictor of mortality in the acute care setting of advanced age population","volume":"44","author":"Breuer","year":"2017","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.numecd.2026.104755_bib36","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/ehf2.14535","article-title":"Uric acid is a biomarker for heart failure, but not therapeutic target: result from a comprehensive meta-analysis","volume":"11","author":"Qin","year":"2024","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.numecd.2026.104755_bib37","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.amjcard.2011.12.018","article-title":"Prognostic value of uric acid in patients with acute coronary syndromes","volume":"109","author":"Ndrepepa","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.numecd.2026.104755_bib38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2143\/AC.60.5.2004969","article-title":"Serum uric acid levels as a predictor of in-hospital death in patients hospitalized for decompensated heart failure","volume":"60","author":"Cengel","year":"2005","journal-title":"Acta Cardiol"},{"key":"10.1016\/j.numecd.2026.104755_bib39","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1253\/circj.70.1006","article-title":"Serum level of uric acid, partly secreted from the failing heart, is a prognostic marker in patients with congestive heart failure","volume":"70","author":"Sakai","year":"2006","journal-title":"Circ J : official journal of the Japanese Circulation Society"},{"key":"10.1016\/j.numecd.2026.104755_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.rdc.2013.10.004","article-title":"Gout and the heart","volume":"40","author":"Bhole","year":"2014","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.numecd.2026.104755_bib41","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/ar3199","article-title":"Epidemiology of gout","volume":"12","author":"Roddy","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.numecd.2026.104755_bib42","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1471-2261-13-115","article-title":"Uric acid is a risk factor for ischemic stroke and all-cause mortality in the general population: a gender specific analysis from the tromso study","volume":"13","author":"Storhaug","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.numecd.2026.104755_bib43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/2047487313519346","article-title":"Uric acid and cardiovascular disease risk reclassification: findings from NHANES III","volume":"22","author":"Zalawadiya","year":"2015","journal-title":"European journal of preventive cardiology"},{"key":"10.1016\/j.numecd.2026.104755_bib44","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104755_bib45","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of Xanthine oxidase inhibition in hyperuricemic heart failure patients: the Xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.numecd.2026.104755_bib46","doi-asserted-by":"crossref","first-page":"R63","DOI":"10.1186\/ar2978","article-title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","volume":"12","author":"Becker","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.numecd.2026.104755_bib47","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.numecd.2026.104755_bib48","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.numecd.2026.104755_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2025.7453","article-title":"Treat-to-Target urate-lowering treatment and cardiovascular outcomes in patients with gout","author":"Cipolletta","year":"2026","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.numecd.2026.104755_bib50","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1136\/annrheumdis-2017-212534","article-title":"MR-PheWAS: exploring the causal effect of SUA level on multiple disease outcomes by using genetic instruments in UK biobank","volume":"77","author":"Li","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.numecd.2026.104755_bib51","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.numecd.2026.104755_bib52","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.cmet.2024.10.014","article-title":"Bempedoic acid suppresses diet-induced hepatic steatosis independently of ATP-citrate lyase","volume":"37","author":"Liu","year":"2025","journal-title":"Cell Metab"},{"key":"10.1016\/j.numecd.2026.104755_bib53","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1194\/jlr.M400018-JLR200","article-title":"Effects of a novel dual lipid synthesis inhibitor and its potential utility in treating dyslipidemia and metabolic syndrome","volume":"45","author":"Cramer","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1016\/j.numecd.2026.104755_bib54","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(23)00316-9","article-title":"Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR outcomes randomised trial","volume":"12","author":"Ray","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.numecd.2026.104755_bib55","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.numecd.2026.104755_bib56","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacl.2022.03.001","article-title":"Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials","volume":"16","author":"Laufs","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2026.104755_bib57","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jacc.2024.04.048","article-title":"Comparative cardiovascular benefits of bempedoic acid and Statin drugs","volume":"84","author":"Lincoff","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.numecd.2026.104755_bib58","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.jacl.2023.10.011","article-title":"Safety of bempedoic acid in patients at high cardiovascular risk and with statin intolerance","volume":"18","author":"Bays","year":"2024","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.numecd.2026.104755_bib59","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1124\/jpet.123.001890","article-title":"Significance of organic anion transporter 2 and organic cation transporter 2 in creatinine clearance: mechanistic evaluation using freshly prepared human primary renal proximal tubule cells","volume":"388","author":"Mathialagan","year":"2024","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.numecd.2026.104755_bib60","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1248\/bpb.33.498","article-title":"Renal secretion of uric acid by organic anion transporter 2 (OAT2\/SLC22A7) in human","volume":"33","author":"Sato","year":"2010","journal-title":"Biol Pharmaceut Bull"},{"key":"10.1016\/j.numecd.2026.104755_bib62","article-title":"Frequency of gout adverse events with bempedoic acid or placebo in those receiving uric acid lowering therapies as prophylaxis or treatment after a gout episode - insights from CLEAR outcomes","author":"Ray","year":"2025","journal-title":"ESC Congress, 28 August - 1 September 2025, Madrid"},{"key":"10.1016\/j.numecd.2026.104755_bib63","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/ATVBAHA.119.313224","article-title":"Soluble uric acid promotes atherosclerosis via AMPK (AMP-activated protein Kinase)-Mediated inflammation","volume":"40","author":"Kimura","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.numecd.2026.104755_bib64","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"Officers","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.numecd.2026.104755_bib65","article-title":"Hyperuricemia associated with thiazide diuretics in hypertensive adults","volume":"11","author":"Raja","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.numecd.2026.104755_bib66","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11883-022-01054-2","article-title":"Bempedoic acid: for whom and when","volume":"24","author":"Ruscica","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.numecd.2026.104755_bib67","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12933-023-02022-z","article-title":"Safety and efficacy of bempedoic acid: a systematic review and meta-analysis of randomised controlled trials","volume":"22","author":"De Filippo","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.numecd.2026.104755_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003121","article-title":"Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis","volume":"17","author":"Cicero","year":"2020","journal-title":"PLoS Med"}],"container-title":["Nutrition, Metabolism and Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326002176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939475326002176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:56:08Z","timestamp":1786650968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939475326002176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0939475326002176"],"URL":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104755","relation":{},"ISSN":["0939-4753"],"issn-type":[{"value":"0939-4753","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bempedoic acid and increased serum uric acid levels: a matter of concern?","name":"articletitle","label":"Article Title"},{"value":"Nutrition, Metabolism and Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.numecd.2026.104755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104755"}}